2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Conditions
Melanoma
105
Carcinoma, Renal Cell
38
Leukemia, Myeloid, Acute
36
Neoplasm Metastasis
31
Neoplasms
22
Breast Neoplasms
22
Lymphoma, Non-Hodgkin
21
Kidney Neoplasms
20
Leukemia
18
Carcinoma, Non-Small-Cell Lung
18
Skin Neoplasms
17
Neuroblastoma
17
Ovarian Neoplasms
16
Colorectal Neoplasms
16
Recurrence
14
Leukemia, Lymphocytic, Chronic, B-Cell
14
Lymphoma
13
Myelodysplastic Syndromes
10
Uveal Melanoma
9
Precursor Cell Lymphoblastic Leukemia-Lymphoma
9
Lymphoma, Follicular
9
Head and Neck Neoplasms
9
Uterine Cervical Neoplasms
8
Multiple Myeloma
8
Congenital Abnormalities
8
Triple Negative Breast Neoplasms
7
Stomach Neoplasms
7
Lung Neoplasms
7
Hodgkin Disease
7
Squamous Cell Carcinoma of Head and Neck
6
Interventions
pembrolizumab
5
padeliporfin
5
Nivolumab
5
fludarabine
4
aldesleukin
4
Ipilimumab
4
Cyclophosphamide
4
atezolizumab
3
Sunitinib
3
Specimen Handling
3
Paclitaxel
3
Mitomycin
3
Magnetic Resonance Spectroscopy
3
Gemcitabine
3
Drug Therapy
3
Carboplatin
3
Biopsy
3
Abiraterone Acetate
3
vedolizumab
2
olaparib
2
niraparib
2
motexafin gadolinium
2
enfortumab vedotin
2
darolutamide
2
cabozantinib
2
anlotinib
2
abiraterone
2
Therapeutics
2
Suspensions
2
Surveys and Questionnaires
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urogenital Neoplasms
×
Interleukin-2
×
Clear all
NCT05902520
2026-01-08
ACT
AgonOx, Inc.
Phase 1
Active not recruiting
18 enrolled